Skip to main content
MIRA
NASDAQ Life Sciences

MIRA Pharmaceuticals Reaffirms Going Concern, Reports Reduced Net Loss and Extended Cash Runway into Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.979
Mkt Cap
$41.14M
52W Low
$0.9
52W High
$2.45
52W Position info
8.8% above low
Off High info
60% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MIRA is trading near its 52-week low of $0.9 (8.8% above the low).

Summary

MIRA Pharmaceuticals filed its Q1 2026 report, reaffirming its going concern status but showing improved financial performance with a reduced net loss and increased R&D, extending its cash runway into Q1 2027.


Key Events · Corporate Governance and Compliance · MIRA

  • Going Concern Reaffirmed with Extended Runway

    The company reiterated its going concern warning, stating it has insufficient cash for 12 months, but updated its cash runway to extend into at least the first quarter of 2027. Cash on hand as of March 31, 2026, was $4.8 million.

  • Reduced Net Loss and Increased R&D

    MIRA Pharmaceuticals reported a net loss of $1.15 million for Q1 2026, a significant improvement from $1.78 million in Q1 2025. Research and development expenses increased to $524,781 from $314,404 year-over-year, indicating continued investment in its pipeline.

  • Repayment of Related-Party Advance

    The company repaid a $330,607 advance payable to its Chairman and CEO, Erez Aminov, during Q1 2026, reducing related-party liabilities.

  • CEO Awarded RSUs for Clinical Milestone

    CEO Erez Aminov was issued 83,500 fully vested Restricted Stock Units (RSUs) valued at $86,005, following the achievement of a Phase 1 clinical trial milestone for one of the company's drug candidates.


Analysis · MIRA · Life Sciences

This quarterly report provides an updated financial picture for MIRA Pharmaceuticals, reiterating the previously disclosed going concern warning. While the company continues to face liquidity challenges, it reported a significantly reduced net loss and increased research and development spending, alongside a repayment of related-party debt. The updated cash runway into Q1 2027 offers a clearer, albeit still short-term, outlook on its financial viability. Investors should monitor future capital raising efforts and clinical trial progress.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MIRA was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.1M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MIRA - Latest Insights

MIRA
Nov 16, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.6283
Real-time Price: $0.3847 info
Change: -$0.2436 (-39%) info
Market Cap: $15.477M info
MIRA
Oct 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5561
Real-time Price: $0.3847 info
Change: -$0.1714 (-31%) info
Market Cap: $15.477M info
MIRA
Oct 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.681
Real-time Price: $0.3847 info
Change: -$0.2963 (-44%) info
Market Cap: $15.477M info
MIRA
Sep 17, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7101
Real-time Price: $0.3847 info
Change: -$0.3254 (-46%) info
Market Cap: $15.477M info
MIRA
Sep 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7101
Real-time Price: $0.3847 info
Change: -$0.3254 (-46%) info
Market Cap: $15.477M info